Initiative for Medicines Access &Knowledge I-Mak is ranked among crime & legal organizations in Lewes, DE, with an America's Best Score of 70 out of 100, based on its 2025 Form 990.
Initiative for Medicines Access &Knowledge I-Mak is a 501(c)(3) organization, classified under Crime & Legal (NTEE I83). Contributions are tax-deductible.
16192 Coastal Hwy, Lewes, DE 19958-3608
In fiscal year 2025 it reported $1,447,801 in revenue and $2,192,975 in expenses, with contributions making up 97.5% of revenue.
From drug development to drug affordability, the medicines system affects who lives and who dies. Through research, education, and partnerships, i-mak advances solutions to address structural inequity in the medicines system.
Main program · fiscal year 2023
I-mak's 2023 achievements in its three program areas include: Research: I-mak released a research brief that provides new insight into the profound impact of extended patent protection that limits biosimilar competition and maintains high drug prices for patients and payers. Additionally, we collaborated with other organizations to produce research reports and submitted responses to requests for p… Read more
I-mak's 2023 achievements in its three program areas include: Research: I-mak released a research brief that provides new insight into the profound impact of extended patent protection that limits biosimilar competition and maintains high drug prices for patients and payers. Additionally, we collaborated with other organizations to produce research reports and submitted responses to requests for public comments at the PTO/fda. Education: Our public education program aimed to make the role of patents central in the drug pricing conversation. I-mak used communications and stakeholder engagement to reveal how structural inequities at every level of the medicines system - brought into sharp focus by the COVID-19 pandemic - lead to unnecessary suffering and death for millions of people worldwide. Policy: I-mak released "addressing patent thickets to improve competition and lower prescription drug prices", which outlines sensible and overdue reforms that will return integrity to the patent system by strengthening transparency, encouraging evidence-based policy, and raising patent quality and inventiveness, all while strengthening competition and helping lower drug prices. This "blueprint for reform" was created using i-mak's participatory changemaking model to generate new solutions by bringing people together who are ideologically, geographically, and sectorally diverse to discuss and shape the future of medicines, starting with the patent system.
$1,260,564 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 81¢ went to programs, 13¢ to management and 6¢ to fundraising.
Programs $1,784,532
Management $286,898
Fundraising $121,545
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
81%
Meets
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$1,447,801Fiscal year 2025
Expenses$2,192,975Fiscal year 2025
Total assets$3,192,663Fiscal year 2025
Total liabilities$231,096Fiscal year 2025
Fiscal year ending December2025
Revenue$1,447,801
Expenses$2,192,975
Net income−$745,174
Net assets$2,961,567
Notable sources of revenue
Percent of total revenue
Contributions
$1,411,169
97.5%
Program services
$0
0.0%
Investment income
$36,173
2.5%
Other (net)
$459
0.0%
Assets / debt
Total assets
$3,192,663
Total liabilities
$231,096
Net assets
$2,961,567
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$1,327,898
Expenses$1,875,049
Net income−$547,151
Net assets$3,706,741
Notable sources of revenue
Percent of total revenue
Contributions
$1,326,416
99.9%
Program services
$0
0.0%
Investment income
$1,482
0.1%
Other (net)
$0
0.0%
Assets / debt
Total assets
$4,263,696
Total liabilities
$556,955
Net assets
$3,706,741
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$2,921,379
Expenses$1,670,896
Net income$1,250,483
Net assets$4,253,892
Notable sources of revenue
Percent of total revenue
Contributions
$2,921,161
100.0%
Program services
$200
0.0%
Investment income
$18
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$4,371,767
Total liabilities
$117,875
Net assets
$4,253,892
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$2,830,909
Expenses$1,565,735
Net income$1,265,174
Net assets$3,003,409
Notable sources of revenue
Percent of total revenue
Contributions
$2,797,092
98.8%
Program services
$33,811
1.2%
Investment income
$6
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$3,143,772
Total liabilities
$140,363
Net assets
$3,003,409
Compensation
Officers and key employees
$303,185
Share of expenses
19.4%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?